Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference


Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time.

A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.


These press releases may also interest you

at 10:16
Nannochloropsis Market to Reach $14.0 Million by 2031 - Exclusive Report by Meticulous Research®
According to a new market research report titled, 'Nannochloropsis Market Size, Share, Forecast, & Trends Analysis by Form (Frozen, Liquid, Powder, Fresh Pastes), Application (Aquafeed, Extraction Companies)- Global Forecast to 2031,' published by...

at 10:15
Exoskeleton Market to Surpass USD 23.6 Billion Valuation by 2031 On the Back of Rising Use of Exoskeletons in Healthcare and Industrial Applications | SkyQuest Technology
According to SkyQuest, the global Exoskeleton Market size was valued at USD 1.58 Billion in 2022 and is poised to grow from USD 2.35 Billion in 2023 to USD 23.6 Billion by 2031, growing at a CAGR of 31.4% in the forecast period (2024-2031)....

at 10:15
NNPBC & Advica Health Expand Services
The Association of Nurses and Nurse Practitioners of BC (NNPBC), the professional association representing all four nursing designations, and Advica Health a Canadian-based health navigation company that provides comprehensive virtual...

at 10:05
Enhancing Technologist Experience and Patient Workflow, Carestream Reveals New Enhancements to CARESTREAM DRX-Evolution Plus System and ImageView Software
Carestream Health announced today the addition of new enhancements to its ImageView Software and DRX-Evolution Plus System, marking the latest improvements to its line of innovative, industry-leading imaging solutions. The latest version of...

at 10:05
Robert G. Miller will always fight for the truth
Recognized throughout his life for his honesty, integrity and philanthropy, Robert G. Miller remains true to himself and asserts his innocence to the charges against him. He once again refutes these false allegations made with the sole objective of...

at 10:01
Rosacea Therapeutics Market to Reach a Value of $8.41 Billion, Growing at a CAGR of 6.1% by 2034
According to a recently released research report by Fact.MR, the global Rosacea Therapeutics Market is expected to reach US$ 4.65 billion in 2024 and is thereafter projected to expand at a CAGR of 6.1% from 2024 to 2034. Advancements in the rosacea...

More news about Health...


News published on and distributed by: